The Niche

One of the questions I get asked most often about pop peptides is why they are so popular. What puts the “pop” in pop peptides? Peptide mania After all, these peptides like Ipamorelin, BPC-157, and so on don’t have clinical trial data to support the uses for which they are being marketed. That makes them […] The post The FDA & compounding pharmacy telehealth connections on pop peptides appeared f…

If you take a statin to improve your lipid profile, someday could you undergo LDL gene editing instead? Might that day be sooner than we think? A new paper has generated great interest in this topic including in the media. LDL gene editing For example, we have: One-and-Done Heart Disease Prevention? Scientists Show It May […] The post Weekly reads: effective LDL gene editing, Chinese genetics gui…

I’ve been following Altos Labs since its inception. The institution has intriguing, ambitious goals. For that reason, it’s been interesting that in terms of news on Altos, things have been relatively quiet for the last 4+ years. Some big changes have happened recently though. Altos Labs is high on talent, but nicely low-key on PR […] The post Did Altos Labs just reprogram itself to focus on AI? P…

Platelet-rich plasma or PRP is a regenerative product that has grown in popularity. The literature on clinical applications of PRP is all over the place. Whether it works or not for any particular application is unclear to me. Many orthopedists seem enthused about it. I haven’t seen any major adverse events linked to PRP. PRP […] The post Weekly reads: odd FDA PRP warning, H3.3 & CTCF, Iowa AG ge…

I’ve been thinking more about the interplay between patient voices and FDA oversight of emerging cell and gene therapies. How do we find integration and balance here? In line with this topic, the FDA’s Megha Kaushal, MD spoke last week in Boston at ASGCT 2026 on patient voices. Kaushal is the Acting Deputy Director, Office […] The post FDA’s Megha Kaushal ASGCT talk: PFDD, patient voices, decisio…

Marty Makary is officially out at the FDA. From STAT: Makary departs FDA amid turmoil as Diamantas, agency’s top food official, steps in. But there’s more going on here in what looks like an agency leadership purge. This is so crazy that it’s hard to imagine a coherent path forward. Next level chaos: Marty Makary […] The post Weekly reads: FDA leadership purge goes beyond Marty Makary, rare gene …

I haven’t written that much about heritable human gene editing recently, but the topic and related technologies are still out there. We need to keep paying attention and having dialogue. For that reason it was great to watch a lively debate in this space between I. Glenn Cohen and Cathy Tie. Some of my more […] The post Perspectives on Cathy Tie v. Glenn Cohen heritable human gene editing debate …

Have we reached the reproductive frontier of lab-grown sperm? Producing oocytes in the lab has always been thought to be the initial focus in this arena. It was thought that figuring out the way to maked lab-grown sperm would take longer. Now a new report suggests both sperm and eggs can be made by in […] The post Weekly reads: lab-grown sperm, stem cell pills, intranasal EVs, EMF Cell paper doub…

I’ve been trying to dig out from all the stuff that piled up while I was working toward a big grant deadline last week, catch up on recent news and papers, and during this time I was excited to see the news about an approved gene therapy for a rare form of deafness. Let’s start […] The post Weekly reads: Gene therapy for rare form of deafness free from Regeneron, OSK in the heart, real-time clini…

Yesterday was Vinay Prasad’s last day as the Director of CBER, the FDA’s biologics branch and as of today Katherine Szarama is Acting Director. Is there some significance to Szarama being acting director? It’s hard to say. Most signs seem to suggest someone else will become the permanent leader. Katherine Szarama background From Politico: “Szarama […] The post Katherine Szarama, PhD, named Acting…

The last 3 weeks have been extremely busy with grant work, but one recent bit of news that caught my eye was UCB’s $1 billion+ acquisition of Neurona. Neurona has been on my radar screen for years. Neurona and stem cells for epilepsy Here’s the news: UCB pays $650M+ for Neurona, marking ‘strategic expansion’ into […] The post Weekly reads: $1B+ Neurona acquisition, cells + organs = better transp…

Vinay Prasad has only less than two  weeks left at the FDA atop CBER. I’ve been trying to imagine where CBER goes from here after he exits. It feels like FDA Commissioner Marty Makary and RFK Jr. will likely be the real leaders of CBER moving forward on key decisions. Under that pressure, will the […] The post Weekly reads: Prasad successor, Sammy Hagar stem cells, more on OSK trial, Finnish spea…

Over the years people have asked me why those selling unproven stem cells and more recently peptides haven’t faced more pushback. Cases do arise, but they often go nowhere. Civil cases like patient lawsuits against stem cell clinics are often settled. These are generally subject to confidentiality agreements. On the peptide front, we’ll have to […] The post Weekly reads: federal stem cell charges…

It’s been a whirlwind of news about pop peptides like BPC-157 and now one of the first indictments related to marketing of these unproven drugs at a clinic. While RFK Jr. may want to unleash previously banned peptides on the public, it hasn’t happened yet. Those still selling these unproven peptides anyway have had to […] The post Landmark federal indictment for pop peptides alleged ‘scheme’ even…

We recently saw exciting news with the first CIRM-funded therapy garnering FDA approval. Before we jump into that and other news and new publications, a reminder that my lab is still crowdfunding to support our brain tumor research in these tough funding times. Please consider making a tax-deductible gift to give more hope for kids and adults facing brain tumors. Thanks! CIRM-funded therapy gets …

Connections between the thymus and aging are growing. Let’s start with that interesting area of research. The thymus and aging In Histology class at the med school here we teach that the thymus just naturally involutes. It mostly turns to adipose tissue with age, which is a depressing thought. A new paper suggests that there are degrees of thymic regression and loss of function. It reports that r…

The FDA is reporting that someone in the US died after use of a regenerative medicine product imported from Japan called Laennec. Here’s the FDA report on the death related to Laennec. The agency advisory is titled: Patient and Consumer Warning about Potential Serious Risks of Harm following Use of Unapproved Products from Human Cells or Tissues. At least one other person has reportedly died afte…

RFK Jr. might be the biggest peptides fan of all. Or it could be the compounding pharmacy industry or Joe Rogan. For a few years, compounders were profiting from marketing the most popular of these unproven peptide drugs (what I call “pop peptides”). The FDA put a halt to that in 2023. The agency at that point blocked specific peptide compounding due to lack of data and safety concerns. So, what …

There have been more revelations about connections between George Church & Epstein in the past few weeks from the new Epstein files document drop. Church & Epstein I wrote earlier about how Jeffrey Epstein interacted with a team at Harvard/MGH. This included George Church and his colleague at the time Joe Thakuria. There were discussions about doing research on Epstein’s cells. Most of the questi…

Before we dive into the weekly reads, I wanted to explain something new on The Niche and ask for your support of our brain tumor research. Brain tumor research funding As many of you know, some firsthand, funding is extremely difficult to get these days. This is particularly true for NIH funding. Some NIH institutes are only funding 4-5% of applications. Foundations supporting brain tumor researc…